On May 26, ImmunityBio rose 5.66% in regular trading, trading at $7.585/share, with trading volume of $24.38 million. The stock rebounded following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively.

The rebound was supported by positive efficacy comparison data presented at the American Urological Association 2026 Annual Meeting. ImmunityBio disclosed that its Nai combined with BCG therapy demonstrated favorable complete response rates compared to Nadofaragene and TAR-200 in BCG-unresponsive non-muscle invasive bladder cancer patients. Additionally, a health economics analysis presented at ISPOR 2026 showed that ANKTIVA plus BCG achieves higher sustained complete response rates at lower cost versus TAR-200.

Following concentrated profit-taking that drove the prior two-session decline on elevated volume, selling pressure appears to have been largely absorbed. The current session saw trading volume stabilize near recent levels, suggesting renewed buyer interest as the market re-prices the clinical data catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)